Group One Trading
ZNTL icon

Group One Trading’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Group One Trading’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,900
Closed -$22.5K – 9326
2025
Q3 		$22.5K Sell
14,900
-10,700
-42% -$16K ﹤0.01% 6608
2025
Q2 		$29.7K Sell
25,600
-44,400
-63% -$58.6K ﹤0.01% 5992
2025
Q1 		$111K Buy
70,000
+20,000
+40% +$43.1K ﹤0.01% 4509
2024
Q4 		$152K Buy
50,000
+44,800
+862% +$147K ﹤0.01% 4158
2024
Q3 		$19.1K Buy
5,200
+200
+4% +$727 ﹤0.01% 5255
2024
Q2 		$20.4K Buy
+5,000
New +$55.8K ﹤0.01% 5209
2023
Q4 		– Sell
-100
Closed -$2.01K – 8314
2023
Q3 		$2.01K Hold
100
– – ﹤0.01% 7043
2023
Q2 		$2.82K Buy
+100
New +$2.4K ﹤0.01% 6964
2021
Q4 		– Sell
-200
Closed -$13K – 8945
2021
Q3 		$13K Hold
200
– – ﹤0.01% 7398
2021
Q2 		$11K Buy
+200
New +$10.7K ﹤0.01% 7488

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Group One Trading's ZNTL Position: Q2 2026 in Review

Group One Trading sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2026, closing a stake of 1,460 shares — an estimated $3.42K sold.

Group One Trading first reported a position in ZNTL in Q2 2022 and held it in 7 quarters. The position peaked at $433K in Q4 2023. 113 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Group One Trading reported no remaining Zentalis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Group One Trading sold 1,460 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $3.42K.
  • Group One Trading first reported a position in Zentalis Pharmaceuticals in Q2 2022 and held it in 7 quarters.
  • Group One Trading's Zentalis Pharmaceuticals position peaked at $433K in Q4 2023.
  • 113 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.